Search

Your search keyword '"A D’Arminio Monforte"' showing total 3,250 results

Search Constraints

Start Over You searched for: Author "A D’Arminio Monforte" Remove constraint Author: "A D’Arminio Monforte"
3,250 results on '"A D’Arminio Monforte"'

Search Results

1. Clinical and laboratory predictors of mpox severity and duration: an Italian multicentre cohort study (mpox-Icona)Research in context

2. Clinical Outcome and 7-Day Virological Clearance in High-Risk Patients with Mild–Moderate COVID-19 Treated with Molnupiravir, Nirmatrelvir/Ritonavir, or Remdesivir

3. Auditing HIV Testing Rates across Europe: Results from the HIDES 2 Study.

4. Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort

5. SARS-CoV-2 mRNA vaccination and short-term changes in viral load and CD4/CD8 T-cell counts in people living with HIV

6. Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options—the ICONA Foundation cohort study

7. IAPAC–Lancet HIV Commission on the future of urban HIV responses

8. Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study

10. Development of the HIV360 international core set of outcome measures for adults living with HIV: A consensus process

11. Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort

12. Heavily treatment-experienced persons living with HIV currently in care in Italy: characteristics, risk factors, and therapeutic options—the ICONA Foundation cohort study

14. Host genetics and COVID-19 severity: increasing the accuracy of latest severity scores by Boolean quantum features

15. Dynamics of viral DNA shedding and culture viral DNA positivity in different clinical samples collected during the 2022 mpox outbreak in Lombardy, Italy

16. Persistent poor clinical outcomes of people living with HIV presenting with AIDS and late HIV diagnosis – results from the ICONA cohort in Italy, 2009-2022

17. Impact of COVID-19 pandemic on retention in care of native and migrant people with HIV in the ICONA cohort

18. Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the ICONA network

19. Efficacy and Safety of Reparixin in Patients with Severe COVID-19 Pneumonia: A Phase 3, Randomized, Double-Blind Placebo-Controlled Study

20. EuCARE-POSTCOVID Study: a multicentre cohort study on long-term post-COVID-19 manifestations

21. Associations between change in BMI and the risk of hypertension and dyslipidaemia in people receiving integrase strand-transfer inhibitors, tenofovir alafenamide, or both compared with other contemporary antiretroviral regimens: a multicentre, prospective observational study from the RESPOND consortium cohorts

22. Dynamics of viral DNA shedding and culture viral DNA positivity in different clinical samples collected during the 2022 mpox outbreak in Lombardy, Italy

23. Persistent poor clinical outcomes of people living with HIV presenting with AIDS and late HIV diagnosis – results from the ICONA cohort in Italy, 2009-2022

24. Longitudinal trends in causes of death among adults with HIV on antiretroviral therapy in Europe and North America from 1996 to 2020: a collaboration of cohort studies

26. Characterization and outcomes of difficult-to-treat patients starting modern first-line ART regimens: Data from the ICONA cohort

27. Association between SARS-CoV-2 RNAemia, skewed T cell responses, inflammation, and severity in hospitalized COVID-19 people living with HIV

28. Differences in clinical characteristics and quantitative lung CT features between vaccinated and not vaccinated hospitalized COVID-19 patients in Italy

29. Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration

30. HIV-1 drug resistance in people on dolutegravir-based antiretroviral therapy: a collaborative cohort analysis

31. Risk of COVID-19 in-hospital mortality in people living with HIV compared to general population according to age and CD4 strata: data from the ICONA network

32. Pillars of long-term antiretroviral therapy success

33. Pillars of long-term antiretroviral therapy success

34. Compassionate Use of Remdesivir for Patients with Severe Covid-19

35. Life expectancy after 2015 of adults with HIV on long-term antiretroviral therapy in Europe and North America: a collaborative analysis of cohort studies

36. Mpox in people with advanced HIV infection: a global case series

37. Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)

38. Determinants of worse liver-related outcome according to HDV infection among HBsAg positive persons living with HIV: Data from the ICONA cohort

39. Association between markers of hepatitis B virus infection and risk of virological rebound in people with HIV receiving antiretroviral therapy

40. Monoclonal antibodies against SARS-CoV-2 to prevent COVID-19 worsening in a large multicenter cohort

41. Influence of efavirenz and 8-hydroxy-efavirenz plasma levels on cognition and central nervous system side effects

42. Trends in mortality in people with HIV from 1999 to 2020: a multi-cohort collaboration

43. Long-term outcomes of bictegravir/emtricitabine/tenofovir alafenamide as first-line therapy and as switch strategy in virologically suppressed persons with HIV: data from the ICONA cohort

44. Association between SARS-CoV-2 RNAemia and dysregulated immune response in acutely ill hospitalized COVID-19 patients

45. Chronic liver enzyme elevation and use of contemporary ARVs among persons living with HIV

46. Clinical characteristics of women with HIV in the RESPOND cohort: A descriptive analysis and comparison to men

47. What is the impact of SARS-CoV-2 pandemic on antimicrobial stewardship programs (ASPs)? The results of a survey among a regional network of infectious disease centres

49. Sarilumab plus standard of care vs standard of care for the treatment of severe COVID-19: a phase 3, randomized, open-labeled, multi-center study (ESCAPE study)Research in context

50. Associations between integrase strand-transfer inhibitors and cardiovascular disease in people living with HIV: a multicentre prospective study from the RESPOND cohort consortium

Catalog

Books, media, physical & digital resources